中华肿瘤杂志2019年12月第41卷第12期ChinJOncol,December2019,Vol.41,No.12 ·890· trialinregionallyadvancedunresectablenon?smallcelllungcontrolledtrialofresectionversusradiotherapyafterinduction cancer:RadiationTherapyOncologyGroup,EasternCooperativechemotherapyinstageⅢA?N2non?smallcelllungcancer[J].J OncologyGroup,andSouthwestOncologyGroup[J].Chest,ThoracOncol,2007,2(8):684?685.DOI:10.1097/JTO. 2000,117(2):358?364.DOI:10.1378/chest.117.2.358.0b013e31811f47ad. [24]MillerED,FisherJL,HaglundKE,etal.Theadditionof[33]AlbainKS,SwannRS,RuschVW,etal.Radiotherapyplus chemotherapytoradiationtherapyimprovessurvivalinelderlychemotherapywithorwithoutsurgicalresectionforstageⅢnon? patientswithstageⅢnon?smallcelllungcancer[J].JThoracsmall?celllungcancer:aphaseⅢrandomisedcontrolledtrial[J]. Oncol,2018,13(3):426?435.DOI:10.1016/j.jtho.2017.11.Lancet,2009,374(9687):379?386.DOI:10.1016/s0140?6736 135.(09)60737?6. [25]LiangJ,BiN,WuS,etal.Etoposideandcisplatinversus[34]PlessM,StuppR,RisHB,etal.Inductionchemoradiationin paclitaxelandcarboplatinwithconcurrentthoracicradiotherapyinstageⅢA/N2non?small?celllungcancer:aphase3randomised unresectablestageⅢnon?smallcelllungcancer:amulticentertrial[J].Lancet,2015,386(9998):1049?1056.DOI:10.1016/ randomizedphaseⅢtrial[J].AnnOncol,2017,28(4):777?S0140?6736(15)60294?X. 783.DOI:10.1093/annonc/mdx009.[35]EberhardtWE,PottgenC,GaulerTC,etal.PhaseⅢstudyof [26]SenanS,BradeA,WangLH,etal.PROCLAIM:randomizedsurgeryversusdefinitiveconcurrentchemoradiotherapyboostin phaseⅢtrialofpemetrexed?cisplatinoretoposide?cisplatinpluspatientswithresectablestageⅢA(N2)andselectedⅢBnon? thoracicradiationtherapyfollowedbyconsolidationchemotherapysmall?celllungcancerafterinductionchemotherapyandconcurrent inlocallyadvancednonsquamousnon?small?celllungcancer[J].Jchemoradiotherapy(ESPATUE)[J].JClinOncol,2015,33 ClinOncol,2016,34(9):953?962.DOI:10.1200/JCO.2015.64.(35):4194?4201.DOI:10.1200/JCO.2015.62.6812. 8824.[36]RuschVW,GirouxDJ,KrautMJ,etal.Inductionchemoradiation [27]AhnJS,AhnYC,KimJH,etal.Multinationalrandomizedphaseandsurgicalresectionforsuperiorsulcusnon?small?celllung Ⅲtrialwithorwithoutconsolidationchemotherapyusingdocetaxelcarcinomas:long?termresultsofSouthwestOncologyGroupTrial andcisplatinafterconcurrentchemoradiationininoperablestage9416(IntergroupTrial0160)[J].JClinOncol,2007,25(3): Ⅲnon?small?celllungcancer:KCSG?LU05?04[J].JClinOncol,313?318.DOI:10.1200/JCO.2006.08.2826. 2015,33(24):2660?2666.DOI:10.1200/JCO.2014.60.0130.[37]WatanabeK,TsuboiM,SakamakiK,etal.Postoperativefollow? [28]BradleyJD,PaulusR,KomakiR,etal.Standard?doseversusupstrategybasedonrecurrencedynamicsfornon?small?celllung high?doseconformalradiotherapywithconcurrentandconsolidationcancer[J].EurJCardiothoracSurg,2016,49(6):1624?1631. carboplatinpluspaclitaxelwithorwithoutcetuximabforpatientsDOI:10.1093/ejcts/ezv462. withstageⅢAorⅢBnon?small?celllungcancer(RTOG0617):[38]TobaH,SakiyamaS,OtsukaH,etal.18F?fluorodeoxyglucose arandomised,two?by?twofactorialphase3study[J].Lancetpositronemissiontomography/computedtomographyisusefulin Oncology,2015,16(2):187?199.DOI:10.1016/s1470?2045postoperativefollow?upofasymptomaticnon?small?celllungcancer (14)71207?0.patients[J].InteractCardiovascThoracSurg,2012,15(5):859? [29]MauguenA,LePéchouxC,SaundersMI,etal.Hyperfractionated864.DOI:10.1093/icvts/ivs368. oracceleratedradiotherapyinlungcancer:anindividualpatient[39]WangSY,YeX,OuW,etal.Riskofcerebralmetastasesfor datameta?analysis[J].JClinOncol,2012,30(22):2788?2797.postoperativelocallyadvancednon?small?celllungcancer[J]. DOI:10.1200/JCO.2012.41.6677.LungCancer,2009,64(2):238?243.DOI:10.1016/j.lungcan. [30]AntoniaSJ,VillegasA,DanielD,etal.Durvalumabafter2008.08.012. chemoradiotherapyinstageⅢnon?small?celllungcancer[J].NEngl[40]ParsonsA,DaleyA,BeghR,etal.Influenceofsmoking JMed,2017,377(20):1919?1929.DOI:10.1056/NEJMoa1709937.cessationafterdiagnosisofearlystagelungcanceronprognosis: [31]AntoniaSJ,VillegasA,DanielD,etal.Overallsurvivalwithsystematicreviewofobservationalstudieswithmeta?analysis[J]. durvalumabafterchemoradiotherapyinstageⅢNSCLC[J].NBMJ,2010,340:b5569.DOI:10.1136/bmj.b5569. EnglJMed,2018,379(24):2342?2350.DOI:10.1056/ NEJMoa1809697. (收稿日期:2019?09?18) [32]VansteenkisteJ,BetticherD,EberhardtW,etal.Randomized 读者·作者·编者 ·· 本刊“专题综论”栏目征稿启事 本刊“专题综论”栏目系高级述评类特色栏目,设栏的同时,结合自身以及国内外他人的工作和经验,有分析、有 20余年来,发表了大量高质量的论文。以往该栏属特约组稿比较、有评论、有观点、有展望地写出具有导向性的评论性文 栏目,不接受自由投稿,旨在按照栏目的特定需要,有指向地章。这种论文的重要性和学术价值,毫不逊于原始论著,甚 选题,组织权威专家著文,提供广大读者参考。今为适应当至过之。 前科技迅速发展的形势,提高本栏目的报道效率,特改变组论文篇幅限制在5000字以内,附中、英文指示性摘要, 稿方式,面向广大作者征稿。凡符合本刊“专题综论”栏目要不附图表,参考文献应精选最主要者,数量不要太多,15篇以 求的来稿,均可为本刊接受,获得发表机会。内为宜。文字力求简洁明了,通顺流畅。 “专题综论”专栏所刊出的文稿不同于一般综述,不能仅 本刊编辑部 限于客观报道最新进展,而是要求作者在综合最新科技进展 |
|